---
title: "Median Technologies partners with Canon’s Olea Medical to commercialize eyonis LCS lung cancer screening software"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294390643.md"
description: "Median Technologies has entered a global commercialization agreement with Olea Medical, a Canon unit, for its eyonis LCS lung cancer screening AI software. Olea will co-market the product in the US and Europe, leveraging Canon's CT imaging base. The commercial rollout is scheduled after FDA 510(k) clearance in February 2026 and CE marking in July 2026. Median employs a multi-channel strategy including direct sales and partnerships like Tempus AI."
datetime: "2026-07-30T15:53:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294390643.md)
  - [en](https://longbridge.com/en/news/294390643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294390643.md)
generator: "portal-rs"
---

# Median Technologies partners with Canon’s Olea Medical to commercialize eyonis LCS lung cancer screening software

-   Median Technologies signed a global commercialization agreement with Olea Medical, a Canon Medical Systems unit, for its eyonis LCS lung cancer screening AI software. \* Olea will co-market the product in the US and Europe, leveraging Canon’s installed base in CT imaging used for lung screening. \* The deal targets commercial rollout following FDA 510(k) clearance in February 2026 and CE marking in July 2026. \* Median is pursuing a multi-channel go-to-market model combining direct sales with non-exclusive distribution partnerships, including an earlier tie-up with Tempus AI. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CAJPY.US](https://longbridge.com/en/quote/CAJPY.US.md)
- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)
- [7751.JP](https://longbridge.com/en/quote/7751.JP.md)

## Related News & Research

- [Tempus AI Diagnostics CEO Thomas Edward Schoenherr reports $188,580 Tempus AI common share sale](https://longbridge.com/en/news/297014369.md)
- [Rhoen-Klinikum invests in Canon fluoroscopy system to upgrade Frankfurt (Oder) endoscopy unit](https://longbridge.com/en/news/296865416.md)
- [Security Risk Advisors Launches SCALR AI as a Free SOC AI Platform for Security Teams](https://longbridge.com/en/news/297523531.md)
- [This Little-Known Software Stock Just Set a New All-Time High](https://longbridge.com/en/news/297539706.md)
- [Do Wall Street Analysts Like Teledyne Technologies Stock?](https://longbridge.com/en/news/297204760.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**